$504 Million is the total value of VHCP Management III, LLC's 18 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | Sell | Axsome Therapeutics Inc | $160,001,000 | +390.6% | 1,547,994 | -3.9% | 31.77% | +57.8% |
| CNST | Buy | Constellation Pharmaceuticals | $118,540,000 | +27403.5% | 2,516,242 | +3674.3% | 23.54% | +8748.5% |
| MIST | Milestone Pharmaceuticals Inc | $33,085,000 | -14.2% | 2,066,529 | 0.0% | 6.57% | -72.4% | |
| RLMD | New | Relmada Therapeutics Inc | $29,950,000 | – | 767,938 | +100.0% | 5.95% | – |
| ETNB | New | 89Bio Inc | $25,206,000 | – | 958,765 | +100.0% | 5.00% | – |
| TXG | 10X Genomics Inc. | $22,875,000 | +51.3% | 300,000 | 0.0% | 4.54% | -51.3% | |
| FTSV | New | Forty Seven Inc | $20,330,000 | – | 516,381 | +100.0% | 4.04% | – |
| ITCI | New | Intra-Cellular Therapies Inc | $19,728,000 | – | 575,000 | +100.0% | 3.92% | – |
| ISEE | New | Iveric Bio Inc | $14,584,000 | – | 1,699,797 | +100.0% | 2.90% | – |
| KALV | Sell | Kalvista Pharmaceuticals | $11,041,000 | +49.2% | 619,905 | -2.8% | 2.19% | -52.0% |
| ADVM | New | Adverum Biotechnologies Inc | $10,901,000 | – | 946,234 | +100.0% | 2.16% | – |
| MRNS | Buy | Marinus Pharmaceuticals Inc | $10,835,000 | +179.6% | 5,016,164 | +99.4% | 2.15% | -10.1% |
| MRSN | New | Mersana Therapeutics Inc | $8,947,000 | – | 1,561,389 | +100.0% | 1.78% | – |
| MYOV | New | Myovant Sciences Ltd | $7,066,000 | – | 455,255 | +100.0% | 1.40% | – |
| NXTC | New | Nextcure Inc | $6,742,000 | – | 119,693 | +100.0% | 1.34% | – |
| OBSV | Sell | Obseva SA | $3,095,000 | -68.0% | 810,264 | -30.1% | 0.62% | -89.7% |
| PTGX | Sell | Protagonist Therapeutics Inc | $571,000 | -95.6% | 80,929 | -92.5% | 0.11% | -98.6% |
| BLPH | Sell | Bellerophon Therapeutics | $134,000 | -88.5% | 383,955 | -84.1% | 0.03% | -96.2% |
| PRVL | Exit | Prevail Therapeutics Inc | $0 | – | -4,408 | -100.0% | -0.03% | – |
| PTI | Exit | Proteostasis Therapeutics Inc | $0 | – | -221,267 | -100.0% | -0.12% | – |
| RDUS | Exit | Radius Health Inc | $0 | – | -23,131 | -100.0% | -0.37% | – |
| KNSA | Exit | Kiniksa Pharmaceuticals Ltd | $0 | – | -277,137 | -100.0% | -1.46% | – |
| TCDA | Exit | Tricida Inc | $0 | – | -80,348 | -100.0% | -1.53% | – |
| BCRX | Exit | BioCryst Pharmaceuticals Inc | $0 | – | -2,708,207 | -100.0% | -4.79% | – |
| LJPC | Exit | La Jolla Pharmaceuticals | $0 | – | -1,251,898 | -100.0% | -6.80% | – |
| RARX | Exit | Ra Pharmaceuticals | $0 | – | -670,350 | -100.0% | -9.79% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kalvista Pharmaceuticals | 6 | Q4 2019 | 21.5% |
| Obseva SA | 6 | Q4 2019 | 15.8% |
| Constellation Pharmaceuticals | 6 | Q4 2019 | 23.5% |
| Marinus Pharmaceuticals Inc | 6 | Q4 2019 | 5.1% |
| Bellerophon Therapeutics | 6 | Q4 2019 | 1.9% |
| BioCryst Pharmaceuticals Inc | 5 | Q3 2019 | 18.0% |
| Tricida Inc | 5 | Q3 2019 | 15.0% |
| Protagonist Therapeutics Inc | 5 | Q4 2019 | 8.0% |
| Kiniksa Pharmaceuticals Ltd | 5 | Q3 2019 | 6.7% |
| Axsome Therapeutics Inc | 4 | Q4 2019 | 31.8% |
View VHCP Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-22 |
| 4 | 2024-02-08 |
| 4 | 2024-02-01 |
| 4 | 2024-01-29 |
| 4 | 2024-01-24 |
| 4 | 2024-01-19 |
| 4 | 2024-01-16 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-12-29 |
View VHCP Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.